Horizon Pharma PLC (NASDAQ:HZNP) Shares Sold by Teachers Advisors LLC

Teachers Advisors LLC decreased its stake in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 68.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 282,888 shares of the biopharmaceutical company’s stock after selling 609,823 shares during the period. Teachers Advisors LLC’s holdings in Horizon Pharma PLC were worth $4,181,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Sheaff Brock Investment Advisors LLC bought a new position in shares of Horizon Pharma PLC during the first quarter valued at about $148,000. Searle & CO. bought a new position in shares of Horizon Pharma PLC during the first quarter valued at about $781,000. Stevens Capital Management LP bought a new position in shares of Horizon Pharma PLC during the first quarter valued at about $173,000. First Mercantile Trust Co. boosted its position in shares of Horizon Pharma PLC by 2.7% in the first quarter. First Mercantile Trust Co. now owns 11,770 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 310 shares in the last quarter. Finally, Profund Advisors LLC boosted its position in shares of Horizon Pharma PLC by 0.8% in the first quarter. Profund Advisors LLC now owns 13,508 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 112 shares in the last quarter. Institutional investors own 82.95% of the company’s stock.

Shares of Horizon Pharma PLC (NASDAQ HZNP) opened at 13.46 on Tuesday. The company’s 50-day moving average is $12.12 and its 200 day moving average is $13.85. The company’s market cap is $2.19 billion. Horizon Pharma PLC has a 1-year low of $9.45 and a 1-year high of $23.44.

Horizon Pharma PLC (NASDAQ:HZNP) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.29. The business had revenue of $289.51 million for the quarter, compared to the consensus estimate of $237.01 million. Horizon Pharma PLC had a negative net margin of 21.26% and a positive return on equity of 21.51%. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.56 EPS. Equities analysts anticipate that Horizon Pharma PLC will post $0.99 EPS for the current year.

Horizon Pharma PLC declared that its board has approved a share repurchase plan on Monday, May 8th that allows the company to buyback 1,000% of outstanding shares. This buyback authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Shares buyback plans are often a sign that the company’s board believes its stock is undervalued.

WARNING: “Horizon Pharma PLC (NASDAQ:HZNP) Shares Sold by Teachers Advisors LLC” was reported by BBNS and is owned by of BBNS. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/horizon-pharma-plc-nasdaqhznp-shares-sold-by-teachers-advisors-llc/1408312.html.

Several brokerages recently issued reports on HZNP. UBS AG set a $16.00 price target on shares of Horizon Pharma PLC and gave the company a “buy” rating in a research report on Wednesday, June 7th. BMO Capital Markets reiterated a “buy” rating and set a $17.00 price target on shares of Horizon Pharma PLC in a research report on Friday, July 28th. BidaskClub cut shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Piper Jaffray Companies set a $18.00 price target on shares of Horizon Pharma PLC and gave the company a “buy” rating in a research report on Monday. Finally, Cantor Fitzgerald set a $13.00 price target on shares of Horizon Pharma PLC and gave the company a “buy” rating in a research report on Monday, July 31st. Five investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $19.57.

In other Horizon Pharma PLC news, Director Michael G. Grey bought 10,000 shares of the business’s stock in a transaction on Wednesday, May 10th. The shares were acquired at an average price of $9.48 per share, with a total value of $94,800.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 3.20% of the company’s stock.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with our FREE daily email newsletter.

 


Latest News

Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns
Darren Daulton Former Catcher with Phillies Dies
Darren Daulton Former Catcher with Phillies Dies


Leave a Reply

 
© 2006-2017 BBNS.